MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Search

Smith & Nephew PLC ADR

Uždarymo kaina

31.72 -2.67

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.52

Max

32.62

Pagrindiniai rodikliai

By Trading Economics

Pajamos

35M

331M

Pardavimai

203M

3.2B

P/E

Sektoriaus vid.

22.091

56.063

Dividendų pajamingumas

2.48

Pelno marža

10.368

Darbuotojai

16,988

EBITDA

133M

856M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+8.77% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.48%

2.45%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.8B

13B

Ankstesnė atidarymo kaina

34.39

Ankstesnė uždarymo kaina

31.72

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Smith & Nephew PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-06 23:17; UTC

Uždarbis

Samsung Forecasts Record First-Quarter Operating Profit

2026-04-06 23:00; UTC

Karštos akcijos

Stocks to Watch: Health Insurers, Mawson, Owlet

2026-04-06 22:13; UTC

Pagrindinės rinkos jėgos

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

2026-04-06 21:46; UTC

Įsigijimai, susijungimai, perėmimai

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

2026-04-06 17:09; UTC

Pagrindinės rinkos jėgos

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026-04-06 16:56; UTC

Svarbiausios naujienos

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

2026-04-06 14:47; UTC

Pagrindinės rinkos jėgos

Stereotaxis Shares Rise on FDA Clearance for Synchrony

2026-04-07 00:00; UTC

Svarbiausios naujienos

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

2026-04-06 23:58; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

2026-04-06 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

2026-04-06 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

2026-04-06 23:15; UTC

Rinkos pokalbiai

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

2026-04-06 22:52; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-06 22:52; UTC

Rinkos pokalbiai

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

2026-04-06 22:14; UTC

Rinkos pokalbiai

Correction to Live Cattle Futures Article

2026-04-06 20:56; UTC

Rinkos pokalbiai

Mexican Private Consumption Fell in January -- Market Talk

2026-04-06 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-06 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-06 19:58; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-06 19:58; UTC

Rinkos pokalbiai

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

2026-04-06 19:11; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

2026-04-06 19:06; UTC

Rinkos pokalbiai

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

2026-04-06 19:03; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-06 19:03; UTC

Rinkos pokalbiai

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

2026-04-06 18:36; UTC

Įsigijimai, susijungimai, perėmimai

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026-04-06 17:59; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

2026-04-06 17:13; UTC

Įsigijimai, susijungimai, perėmimai

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026-04-06 16:33; UTC

Rinkos pokalbiai

Oil Futures Steady as Market Awaits Trump -- Market Talk

2026-04-06 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-06 14:59; UTC

Uždarbis

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Akcijų palyginimas

Kainos pokytis

Smith & Nephew PLC ADR Prognozė

Kainos tikslas

By TipRanks

8.77% į viršų

12 mėnesių prognozė

Vidutinis 34.96 USD  8.77%

Aukščiausias 35 USD

Žemiausias 34.91 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Smith & Nephew PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

26.64 / 28.37Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat